PMC:7172841 / 26171-26460 JSONTXT

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T32","span":{"begin":243,"end":270},"obj":"http://purl.obolibrary.org/obo/GO_0050728"}],"text":"These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T187","span":{"begin":0,"end":289},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T822","span":{"begin":94,"end":103},"obj":"DG_39"},{"id":"T823","span":{"begin":121,"end":132},"obj":"DG_35"},{"id":"T56935","span":{"begin":51,"end":55},"obj":"PR:000001393"},{"id":"T72906","span":{"begin":77,"end":80},"obj":"PR:000029150"},{"id":"T21106","span":{"begin":84,"end":94},"obj":"GO:0010467"},{"id":"T43307","span":{"begin":191,"end":200},"obj":"DG_39"},{"id":"T89983","span":{"begin":218,"end":229},"obj":"DG_35"}],"text":"These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1016","span":{"begin":280,"end":288},"obj":"Species"},{"id":"1017","span":{"begin":94,"end":103},"obj":"Chemical"},{"id":"1018","span":{"begin":105,"end":115},"obj":"Chemical"},{"id":"1019","span":{"begin":121,"end":132},"obj":"Chemical"}],"attributes":[{"id":"A1016","pred":"tao:has_database_id","subj":"1016","obj":"Tax:9606"},{"id":"A1017","pred":"tao:has_database_id","subj":"1017","obj":"MESH:C000592401"},{"id":"A1018","pred":"tao:has_database_id","subj":"1018","obj":"MESH:C504234"},{"id":"A1019","pred":"tao:has_database_id","subj":"1019","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}